With ‘evolved’ treatment landscape, Merck pulls Keytruda’s FDA nod in third-line stomach cancer
Two months after a key FDA panel voted down Merck’s conditional nod for Keytruda as a third-line treatment for certain stomach cancer patients, the company says it’s pulling the plug on the indication. Following consultation with the FDA, Merck on Thursday said it will voluntarily withdraw its U.S. accelerated approval for Keytruda as a third-line… Read More: With ‘evolved’ treatment landscape, Merck pulls Keytruda’s FDA nod in… »